**Table S1. Classification of suspected ADRs by SOC and drug class in women.**

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| **SOCa** | **ACE-inhibitors** | | **ARBs** | | **Totalc** |
| **Mon. N (%)b** | **Comb. N (%)b** | **Mon. N (%)b** | **Comb. N (%)b** | **N (%)b** |
| **General dis. and admin. site conditions** | 28 (2.7) | 19 (1.8) | 31 (3.0) | 50 (4.8) | 128 (12.3) |
| **Vascular disorders** | 12 (1.2) | 11 (1.1) | 16 (1.5) | 27 (2.6) | 66 (6.3) |
| **Respiratory, thoracic and mediastinal disorders** | 31 (3.0) | 19 (1.8) | 6 (0.6) | 9 (0.9) | 65 (6.3) |
| **Investigations** | 10 (1.0) | 9 (0.9) | 8 (0.8) | 14 (1.3) | 41 (3.9) |
| **Nervous system disorders** | 10 (1.0) | 2 (0.2) | 6 (0.6) | 13 (1.3) | 31 (3.0) |
| **Skin and subcutaneous tissue disorders** | 12 (1.2) | 6 (0.6) | 6 (0.6) | 6 (0.6) | 30 (2.9) |
| **Gastrointestinal disorders** | 4 (0.4) | 6 (0.6) | 6 (0.6) | 7 (0.7) | 23 (2.2) |
| **Cardiac disorders** | - | 6 (0.6) | 5 (0.5) | 8 (0.8) | 19 (1.8) |
| **Blood and lymphatic system disorders** | - | - | 5 (0.5) | 6 (0.6) | 11 (1.1) |
| **Renal and urinary disorders** | - | 5 (0.5) | 4 (0.4) | 2 (0.2) | 11 (1.1) |
| **Metabolism and nutrition disorders** | - | 3 (0.3) | 2 (0.2) | 4 (0.4) | 9 (0.9) |
| **Ear and labyrinth disorders** | 3 (0.3) | 3 (0.3) | 1 (0.1) | 2 (0.2) | 9 (0.9) |
| **Psychiatric disorders** | 3 (0.3) | - | 2 (0.2) | 2 (0.2) | 7 (0.7) |
| **Musculoskeletal and connective tissue disorders** | 2 (0.3) | 1 (0.1) | - | 3 (0.3) | 6 (0.6) |
| **Eye disorders** | - | - | 1 (0.1) | 2 (0.2) | 3 (0.3) |
| **Immune system disorders** | 1 (0.1) | 1 (0.1) | - | - | 2 (0.2) |
| **Neoplasms benign, malignant and unspecified** | - | 1 (0.1) | - | - | 1 (0.1) |
| **Congenital, familial and genetic disorders** | - | - | - | 1 (0.1) | 1 (0.1) |
| **Total** | **116 (11.2)** | **92 (8.8)** | **99 (9.5)** | **156 (15.0)** | **463 (44.5)** |

a. SOC = Systemic Organ Class; b. Percentage calculated based on the total number of SOCs (n=1040); c. Total SOCs in women (n=463) exceed the number of reported events in women (n=348) because in several cases more than one adverse event occurred.

Mon = monotherapy; Comb = combination.

**Table S2. Classification of suspected ADRs by SOC and drug class in men.**

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| **SOCa** | **ACE-inhibitors** | | **ARBs** | | **Totalc** |
| **Mon. N (%)b** | **Comb. N (%)b** | **Mon. N (%)b** | **Comb. N (%)b** | **N (%)b** |
| **General dis. and admin. site conditions** | 42 (4.0) | 32 (3.1) | 31 (3.0) | 57 (5.5) | 162 (15.6) |
| **Vascular disorders** | 24 (2.3) | 18 (1.7) | 13 (1.3) | 25 (2.4) | 80 (7.7) |
| **Investigations** | 15 (1.4) | 12 (1.2) | 15 (1.4) | 18 (1.7) | 60 (5.8) |
| **Respiratory thoracic and mediastinal disorders** | 28 (2.7) | 16 (1.5) | 4 (0.4) | 9 (0.9) | 57 (5.5) |
| **Nervous system disorders** | 10 (1.0) | 10 (1.0) | 4 (0.4) | 7 (0.7) | 31 (3.0) |
| **Blood and lymphatic system disorders** | 1 (0.1) | 2 (0.2) | 12 (1.2) | 15 (1.4) | 30 (2.9) |
| **Skin and subcutaneous tissue disorders** | 9 (0.9) | 10 (1.0) | 5 (0.5) | 5 (0.5) | 29 (2.8) |
| **Metabolism and nutrition disorders** | 5 (0.5) | 6 (0.6) | 3 (0.3) | 15 (1.4) | 29 (2.8) |
| **Gastrointestinal disorders** | 12 (1.2) | 6 (0.6) | 2 (0.2) | 4 (0.4) | 24 (2.3) |
| **Cardiac disorders** | 3 (0.3) | 3 (0.3) | 5 (0.5) | 4 (0.4) | 15 (1.4) |
| **Musculoskeletal and connective tissue disorders** | 4 (0.4) | 4 (0.4) | 1 (0.1) | 4 (0.4) | 13 (1.3) |
| **Renal and urinary disorders** | 2 (0.2) | 5 (0.5) | - | 5 (0.5) | 12 (1.2) |
| **Ear and labyrinth disorders** | 4 (0.4) | 2 (0.2) | 1 (0.1) | 5 (0.5) | 12 (1.2) |
| **Reproductive system and breast disorders** | 4 (0.4) | 4 (0.4) | 1 (0.1) | 3 (0.3) | 12 (1.2) |
| **Psychiatric disorders** | 2 (0.2) | - | - | 4 (0.4) | 6 (0.6) |
| **Eye disorders** | 1 (0.1) | - | - | 1 (0.1) | 2 (0.2) |
| **Infections and infestations** | 2 (0.2) | - | - | - | 2 (0.2) |
| **Injury, poisoning and procedural complications** | - | - | 1 (0.1) | - | 1 (0.1) |
| **Total** | **168 (16.2)** | **130 (12.5)** | **98 (9.4)** | **181 (17.4)** | **577 (55.5)** |

a. SOC = Systemic Organ Class; b. Percentage calculated based on the total number of SOCs (n=1040); c. Total SOCs in men (n=577) exceed the number of reported events in women (n=424) because in several cases more than one adverse event occurred.

Mon = monotherapy; Comb = combination.